



5 April 2021

VIA E-MAIL ONLY

James Love

Knowledge Ecology International

1621 Connecticut Ave. NW, Suite 500

Washington, DC 20009

IN RE: Prospective Grant of an Exclusive License (NIH License Application A-107-2021) to Kyverna Therapeutics, published on 18 February 2021 in *Federal Register* Vol. 86, No. 31, page 10092-93

Dear Mr. Love:

Thank you for providing us with your comments regarding the notice of intent to grant a license to Kyverna Therapeutics (Kyverna), by the National Cancer Institute (NCI).

Prior to posting a notice for a proposed grant of an exclusive license, the NCI determines that the criteria set forth in 37 CFR 404.7(a)(1)(ii-iii) have been satisfied and that the company is qualified both technically and financially to be granted an exclusive license to the Government's intellectual property in the fields of use as specified. The notice period provides an opportunity for public comment and possible objection to the proposed license. We consider all comments prior to negotiating the proposed license.

Your suggestions will be given full consideration as we move forward with negotiating an exclusive license to Kyverna for NCI technology E-042-2014-0 in the limited field of use described in the notice. However, NCI has determined that your comments did not raise an issue that would preclude the grant of the proposed exclusive license, and the NCI intends to proceed with the negotiation of the license.

Sincerely,
David A. Lambertson, Ph.D.
Senior Technology Transfer Manager
National Cancer Institute, TTC
david.lambertson@nih.gov